logo-loader
viewArix Bioscience PLC

Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

Harpoon Therapeutics has filed a registration statement with the US Securities and Exchange Commission relating to a proposed underwritten initial public offering

arix
Harpoon is a clinical-stage immuno-oncology company

Harpoon Therapeutics Inc., a portfolio company of Arix Bioscience PLC (LON:ARIX) is planning to float in the US.

Arix said Harpoon has filed a registration statement with the US Securities and Exchange Commission relating to a proposed underwritten initial public offering.

READ: Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy

Harpoon is a clinical-stage immuno-oncology company developing T cells to fight cancer and other diseases.

Quick facts: Arix Bioscience PLC

Price: 111.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £151.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read